Table 3.
Adjusted risk at 30 days for non-survivors and survivors among hospitalized SARS-CoV-2-positive veterans by indicated post-index medication use and race.
| Post-Index | Non Survivors ^ |
Survivors ^ | Multiplicity Corrected ‡ | ||
|---|---|---|---|---|---|
| Medication * | n (%) | n (%) | aRR (95% CI) † | p-Value | |
| Black (N = 3281) | |||||
| Vitamin D | Corticosteroids | ||||
| − | + | 185 (45) | 1089 (38) | 1.0 Referent | --- |
| − | − | 215 (52) | 1633 (57) | 0.69 (0.55–0.86) | 0.0009 |
| + | + | 5 (1) | 70 (2) | 0.44 (0.09–0.2.0) | 0.29 |
| + | − | 5 (1) | 79 (3) | 0.34 (0.12–0.98) | 0.047 |
| White (N = 4291) | |||||
| Vitamin D | Corticosteroids | ||||
| − | + | 329 (50) | 1434 (40) | 1.0 Referent | --- |
| − | − | 318 (48) | 2020 (56) | 0.65 (0.55–0.76) | <0.0001 |
| + | + | 9 (1) | 76 (2) | 0.50 (0.26–0.96) | 0.036 |
| + | − | 6 (1) | 99 (3) | 0.29 (0.12–0.66) | 0.0032 |
^ Non-referent group of the indicated comparison factor. * Systemic administration by mouth or intramuscular injection. † Adjusted for Age (≤60, 61–70, 71–80, >80), Alcohol Use Disorder (Yes, No), BMI (<18.5, 18.5–24.9, 25–29.9, ≥30), Charlson Comorbidity Index (0, 1–2, 3–4, 5+), Current Smoker (Yes, No), Location (Pacific-Mountain, Mid-West/Continental, East Coast), Sex (Male, Female), and Time (March, April–September). ‡ Subset analyses corrected for multiplicity using the Hochberg step-up procedure for multinomial comparisons. aRR = Adjusted relative risk; BMI = body mass index (kg/m2); CI = confidence interval.